Arrays Hold Promise for Cancer Diagnostics, But More Data Is Needed | GenomeWeb

Microarrays have enjoyed center stage in cancer research for a while now, spurring hope that they will become improved diagnostic and prognostic tools. In particular, oncologists would like to use them to predict whether or not a cancer is going to spread in the body, how likely it will respond to a certain type of treatment, and how long the patient will probably survive. But what will it take to translate results from early studies into clinical applications, and what role will microarrays play in this process?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.